Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endothelial transcription factor GATA-2 (GATA2) is a zinc-finger transcription factor that plays a critical role in the development, proliferation, and maintenance of hematopoietic, endothelial, and endocrine cell lineages. It functions as a pioneer factor, binding to consensus DNA sequences to regulate gene expression, including the regulation of endothelin-1 in endothelial cells and the modulation of androgen receptor (AR) expression and activity in prostate cells. GATA2 is highly implicated in various diseases; germline mutations lead to GATA2 deficiency syndrome, characterized by immunodeficiency, lymphedema, and a high predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Conversely, overexpression of GATA2 is a key driver in castration-resistant prostate cancer (CRPC) and chemotherapy-resistant AML, making it an attractive therapeutic target. While there are currently no clinically approved drugs specifically targeting GATA2, small molecules like the repurposed vasodilator dilazep and the experimental compound K-7174 have demonstrated the ability to inhibit GATA2 activity, suppress downstream oncogenic pathways, and induce apoptosis in cancer cells. However, therapeutic targeting of GATA2 poses significant safety challenges, as systemic inhibition may impair normal hematopoiesis, exacerbate immunodeficiency, or cause vascular and thrombotic complications.
Inhibition of GATA2 DNA-binding activity, suppression of GATA2 recruitment to chromatin, and downregulation of downstream transcriptional programs
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endothelial transcription factor GATA-2 (GATA2).